CN102458476B - 用于治疗多发性硬化症的组合物及方法 - Google Patents

用于治疗多发性硬化症的组合物及方法 Download PDF

Info

Publication number
CN102458476B
CN102458476B CN201080026791.5A CN201080026791A CN102458476B CN 102458476 B CN102458476 B CN 102458476B CN 201080026791 A CN201080026791 A CN 201080026791A CN 102458476 B CN102458476 B CN 102458476B
Authority
CN
China
Prior art keywords
multiple sclerosis
medicament
administered
treatment
mis416
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080026791.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102458476A (zh
Inventor
弗朗克·B·戈尔德
吉利安·爱力森·韦伯斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Therapeutics Ltd
Original Assignee
Innate Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Therapeutics Ltd filed Critical Innate Therapeutics Ltd
Publication of CN102458476A publication Critical patent/CN102458476A/zh
Application granted granted Critical
Publication of CN102458476B publication Critical patent/CN102458476B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Photographic Developing Apparatuses (AREA)
  • Fodder In General (AREA)
CN201080026791.5A 2009-06-16 2010-01-16 用于治疗多发性硬化症的组合物及方法 Expired - Fee Related CN102458476B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ5777731 2009-06-16
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis
PCT/NZ2010/000112 WO2010147484A1 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
CN102458476A CN102458476A (zh) 2012-05-16
CN102458476B true CN102458476B (zh) 2014-08-20

Family

ID=42646236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080026791.5A Expired - Fee Related CN102458476B (zh) 2009-06-16 2010-01-16 用于治疗多发性硬化症的组合物及方法

Country Status (20)

Country Link
US (1) US8389479B2 (enExample)
EP (1) EP2442832B1 (enExample)
JP (1) JP5646617B2 (enExample)
CN (1) CN102458476B (enExample)
AU (1) AU2010260585B2 (enExample)
BR (1) BRPI1009606A2 (enExample)
CA (1) CA2688766C (enExample)
CY (1) CY1115714T1 (enExample)
DK (1) DK2442832T3 (enExample)
ES (1) ES2521565T3 (enExample)
HR (1) HRP20141035T1 (enExample)
IL (1) IL216993A (enExample)
IN (1) IN2012DN00167A (enExample)
MX (1) MX2011013661A (enExample)
NZ (1) NZ577731A (enExample)
PL (1) PL2442832T3 (enExample)
PT (1) PT2442832E (enExample)
SI (1) SI2442832T1 (enExample)
SM (1) SMT201400165B (enExample)
WO (1) WO2010147484A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709448B2 (en) * 2008-04-01 2014-04-29 Innate Immunotherapeutics Ltd. Anti-infective agents and uses thereof
LT3722808T (lt) 2010-10-25 2024-12-27 Biogen Ma Inc. Alfa-4 integrino aktyvumo skirtumo, koreliuojančio su skirtumais svcam ir/arba smadcam lygiuose, nustatymo būdai
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
KR20170041116A (ko) * 2015-10-06 2017-04-14 이네이트 이뮤노테라퓨틱스 리미티드 신경계의 보호 및/또는 복구용 조성물 및 방법
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
LT3506921T (lt) 2016-08-31 2023-08-10 Mapi Pharma Ltd Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CA3099946A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
WO2020010221A1 (en) * 2018-07-03 2020-01-09 University Of Florida Research Foundation, Inc. Microparticle systems and their use for the treatment of multiple sclerosis
BR112022024966A2 (pt) * 2020-06-22 2023-01-03 Otivio As Métodos para tratar espasticidade usando composições antiespasmódicas e terapia de pressão negativa

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070564A1 (en) * 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
WO2008150181A1 (en) * 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treating anthrax exposure associated conditions
WO2008150182A1 (en) * 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treatment of anthrax

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043347A (en) * 1996-10-10 2000-03-28 Probe International Inc. Compositions and methods for treating viral infections
BRPI0512921A (pt) * 2004-07-01 2008-04-22 Den Kgl Veterinaer Og Landboho processo para tratamento e profilaxia de ms
JP2008251608A (ja) 2007-03-29 2008-10-16 Casio Comput Co Ltd 半導体装置およびその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070564A1 (en) * 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
WO2008150181A1 (en) * 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treating anthrax exposure associated conditions
WO2008150182A1 (en) * 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treatment of anthrax

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clinical Suppression of Experimental Allergic Encephalomyelitis by Muramyl Dipeptide "Adjuvant";Root-Bernstein,R.S. et al;《Brain Research Bulletin》;19861231;第17卷(第4期);473-476 *
Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres;Tabata,Y,et al;《Journal of Pharmacy and Pharmacology》;19871231;第39卷(第9期);698-704 *

Also Published As

Publication number Publication date
EP2442832B1 (en) 2014-08-06
EP2442832A1 (en) 2012-04-25
CN102458476A (zh) 2012-05-16
CA2688766C (en) 2015-06-30
CA2688766A1 (en) 2010-12-16
SI2442832T1 (sl) 2014-12-31
AU2010260585B2 (en) 2013-02-21
ES2521565T3 (es) 2014-11-12
PT2442832E (pt) 2014-11-11
NZ577731A (en) 2010-08-27
EP2442832A4 (en) 2013-07-03
JP5646617B2 (ja) 2014-12-24
BRPI1009606A2 (pt) 2016-10-11
MX2011013661A (es) 2012-05-22
HK1167101A1 (en) 2013-02-01
IL216993A0 (en) 2012-02-29
WO2010147484A8 (en) 2012-07-19
HRP20141035T1 (hr) 2014-12-19
IL216993A (en) 2016-03-31
WO2010147484A1 (en) 2010-12-23
IN2012DN00167A (enExample) 2015-04-17
JP2012530132A (ja) 2012-11-29
CY1115714T1 (el) 2017-01-25
US20100317589A1 (en) 2010-12-16
SMT201400165B (it) 2015-01-15
US8389479B2 (en) 2013-03-05
AU2010260585A8 (en) 2012-06-14
PL2442832T3 (pl) 2015-01-30
DK2442832T3 (da) 2014-11-10
AU2010260585A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
CN102458476B (zh) 用于治疗多发性硬化症的组合物及方法
Manjunatha et al. Multiple sclerosis: therapeutic strategies on the horizon
DE69837324T2 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
KR20140054129A (ko) 라퀴니모드와 인터페론-베타의 병용에 의한 다발성 경화증의 치료
KR20200101948A (ko) 신경계 질환 치료제
CN107582566A (zh) 通过多胺化合物调控自身免疫性疾病的方法和组合物
US20200246380A1 (en) Pharmaceutical Composition for Preventing or Treating Autoimmune Disease, and Method for Producing Same
US8741847B2 (en) Agent and methods for reducing inflammatory markers
KR101226605B1 (ko) 질병의 치료
US11400131B2 (en) Multi-peptide composition
HK1167101B (en) Compositions and methods for treatment of multiple sclerosis
US20240366954A1 (en) Compositions, systems, and methods for treating cancer using tumor treating fields and killer cells
Al Amin et al. Multiple sclerosis: a comprehensive review of pathophysiology and combined natural-synthetic therapeutic strategies
CA2984957C (en) Multi-peptide composition
Çimen et al. Current perspectives on Multiple Sclerosis
HK1025737B (en) Treatment of multiple sclerosis through ingestion of copolymer-1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: Application Date|International application date

Correct: 20100616

False: 20100116

Number: 34

Volume: 30

CI03 Correction of invention patent

Correction item: Application Date|International application date

Correct: 20100616

False: 20100116

Number: 34

Page: The title page

Volume: 30

ERR Gazette correction

Free format text: CORRECT: APPLICATION DATE; INTERNATIONAL APPLICATION DATE; FROM: 2010.01.16 TO: 2010.06.16

RECT Rectification
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140820

Termination date: 20180616

CF01 Termination of patent right due to non-payment of annual fee